Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control

Novo NordiskUltra-long-acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycaemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego. Data were from two, phase three, 52-week clinical trials, one with individuals with type 1 and one in individuals with type 2 diabetes.(1,2)

Separately, in a late-breaking presentation, data revealed that insulin degludec could be dosed at different times from day to day in a 26-week trial.(3)

"Episodes of low blood sugar, known as hypoglycaemia, are a major concern for many people with diabetes," said Alan Garber, MD, Professor, Departments of Medicine, Baylor College of Medicine, in Houston, Texas, USA. "It is particularly encouraging that insulin degludec significantly reduces the rate of overall hypoglycaemia in type 2 patients and nocturnal hypoglycaemia, in patients with type 1 or type 2 diabetes. The findings of these studies suggest that insulin degludec potentially offers substantial benefits for patients and the management of their diabetes."

Findings include:

  • The 52-week studies were designed to reach similar glycaemic targets for all patients (known as treat-to-target) and at one year patients taking insulin degludec experienced * HbA1C reductions of 0.4% in patients with type 1 diabetes and 1.2% for patients with type 2 diabetes, which was statistically non-inferior to insulin glargine.(1,2)
  • In type 2 patients, a significantly lower rate of hypoglycaemic events with insulin degludec compared to those given insulin glargine (11.1 vs. 13.6 episodes/patient-yr; p=0.0359)(1)
  • Rates of nocturnal hypoglycaemia, classified as occurring between midnight and 5:59 am, were 25% lower in both the type 1 and type 2 diabetes patients taking insulin degludec than those taking insulin glargine (4.4 vs. 5.9 episodes/patient-yr, p = 0.021; and 1.4 vs. 1.8 episodes/patient-yr, p=0.0399, respectively).(1,2)

Also during ADA, data were presented showing possibility to dose insulin degludec at different times from day to day in patients with type 2 diabetes. The study demonstrated that changes in the injection time of insulin degludec from day to day (up to 40 hours apart) did not affect overall glycaemic control or risk of hypoglycaemia when compared to insulin glargine.

Insulin degludec was dosed once daily by alternating morning and evening injections from day to day while insulin glargine was administered at the same time each day, according to its prescribing instructions.(3) Insulin degludec and insulin glargine reduced HbA1C by 1.28 and 1.26 percentage points, respectively.

The trials were 'treat-to-target' studies, meaning insulin was titrated systematically to achieve a target fasting glucose level. Patients in the open-label trials, using insulin degludec and insulin glargine had similar starting glucose levels, allowing researchers to closely determine the differences between the treatments.(4)

1. Garber A. Insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine: 1-year results from randomized basal-bolus trial in people with type 2 diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3582)
2. Heller S. Insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin glargine: 1-year results from randomized basal-bolus trial in people with type 1 diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3583)
3. Meneghini L. Flexible Once-daily Dosing of Insulin Degludec does not Compromise Glycemic Control or Safety Compared to Insulin Glargine Given Once Daily at the Same Time Each Day in People with Type 2 Diabetes. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 26 June 2011. (NN1250-3668)
4. Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention; U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); February 2008 Clinical/Medical = DRAFT GUIDANCE http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071625.pdf

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]